Moderna (NASDAQ:MRNA) and Kiromic BioPharma (NASDAQ:KRBP) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.
Earnings and Valuation
This table compares Moderna and Kiromic BioPharma’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Moderna||$803.40 million||137.97||-$747.06 million||$16.31||16.76|
|Kiromic BioPharma||N/A||N/A||-$19.20 million||($1.89)||-1.56|
Kiromic BioPharma has lower revenue, but higher earnings than Moderna. Kiromic BioPharma is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.
This table compares Moderna and Kiromic BioPharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations for Moderna and Kiromic BioPharma, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Moderna currently has a consensus target price of $237.79, suggesting a potential downside of 13.02%. Given Moderna’s higher probable upside, equities analysts plainly believe Moderna is more favorable than Kiromic BioPharma.
Institutional and Insider Ownership
55.1% of Moderna shares are held by institutional investors. Comparatively, 22.2% of Kiromic BioPharma shares are held by institutional investors. 19.4% of Moderna shares are held by insiders. Comparatively, 34.5% of Kiromic BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Moderna beats Kiromic BioPharma on 8 of the 10 factors compared between the two stocks.
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
About Kiromic BioPharma
Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.